Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT05444465

Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears

Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears — Recruiting • Non-phase study • NCT05444465.

📅 05 Aug 2026 ⏱ 1 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT05444465
Start
2022-08-30
Completion
2026-08-15
ClinicaliQ Trial Snapshot
  • Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears — Recruiting • Non-phase study • NCT05444465.
  • REGENETEN implant may help patients return to daily activities faster than standard repair for partial rotator cuff tears.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The purpose of the study is to assess whether the REGENETEN™ Bioinductive Implant allows patients to get back to their everyday activities quicker than if the tendon is repaired by the standard repair technique 'Completion and Repair' for surgically treating partial-thickness rotator cuff tears. Conditions: Rotator Cuff Injuries Interventions: Isolated Bioinductive Repair, Completion and Repair Lead Sponsor: Smith & Nephew, Inc. Planned Enrollment: 234 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn